As noted in the report by Booth, Page, and Bohlmann, various strains of cannabis plants produce terpenes differently. Commonly, hemp plants contain less terpene-rich resin than marijuana plants. The amount of resin found in hemp plants, however, does not affect the quality of CBD that we obtain from them. In fact, hemp plants are a far better source of CBD than marijuana plants.
The legality of CBD in the US varies from state to state, but at the federal level, CBD is mysteriously classified as a Schedule I drug despite its sourcing. According to the federal government, Schedule I drugs are substances or chemicals with no currently accepted medical use and a high potential for abuse. Other Schedule I drugs include heroin, LSD, marijuana, and ecstasy. However, CBD can be purchased as a dietary supplement throughout the country despite the FDA’s official stance that CBD isn’t a supplement. The landscape of CBD legality in the US is exactly as confusing as it reads; that squirrely, perplexing itch at the back of your brain is cognitive dissonance, and it’s an entirely normal reaction.
Cannabinoids are facilitative of the process of bone metabolism—the cycle in which old bone material is replaced by new at a rate of about 10 percent per year, crucial to maintaining strong, healthy bones over time. CBD in particular has been shown to block an enzyme that destroys bone-building compounds in the body, reducing the risk of age-related bone diseases like osteoporosis and osteoarthritis. In both of those diseases, the body is no longer creating new bone and cartilage cells. CBD helps spur the process of new bone-cell formation, which is why it has been found to speed the healing of broken bones and, due to a stronger fracture callus, decrease the likelihood of re-fracturing the bone (bones are 35–50 percent stronger than those of non-treated subjects).